Kejing Tang

3.9k total citations
126 papers, 2.0k citations indexed

About

Kejing Tang is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kejing Tang has authored 126 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 43 papers in Oncology and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kejing Tang's work include Acute Myeloid Leukemia Research (19 papers), Lung Cancer Treatments and Mutations (18 papers) and CAR-T cell therapy research (16 papers). Kejing Tang is often cited by papers focused on Acute Myeloid Leukemia Research (19 papers), Lung Cancer Treatments and Mutations (18 papers) and CAR-T cell therapy research (16 papers). Kejing Tang collaborates with scholars based in China, United States and Malaysia. Kejing Tang's co-authors include Jianxiang Wang, Qing Rao, Haiyan Xing, Tian Zheng, Min Wang, Yingxi Xu, Saisai Li, Zunfu Ke, Ying Wang and Wenting Jiang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Kejing Tang

114 papers receiving 2.0k citations

Peers

Countries citing papers authored by Kejing Tang

Since Specialization

Citations

This map shows the geographic impact of Kejing Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kejing Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kejing Tang more than expected).

Fields of papers citing papers by Kejing Tang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kejing Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kejing Tang. The network helps show where Kejing Tang may publish in the future.

Co-authorship network of co-authors of Kejing Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Kejing Tang. A scholar is included among the top collaborators of Kejing Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kejing Tang. Kejing Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Liquid chromatography-tandem mass spectrometry for the quantification of ripretinib and its metabolites DP-5439 in human plasma 2025 ·Frontiers in Pharmacology ·Jiahui Lin, Aiting Jiang, (unknown), (unknown), Hao Li, Shirong Cai, Yulong He, Xiao Chen, Guoping Zhong, Kejing Tang, (unknown), (unknown)	1
2	The Clinical and Molecular Characterization of Distinct Subtypes in Adult T Cell Acute Lymphoblastic Leukemia 2025 ·Cancer Science ·Hong Yu, Wenbing Liu, Junping Zhang, (unknown), (unknown), Tian Zheng, Kejing Tang, Haiyan Xing, Ying Wang, Hui Wei, (unknown), Runxia Gu, Min Wang, Huijun Wang, Jianxiang Wang, Shaowei Qiu	0
3	Simultaneous Determination of Osimertinib and its Metabolites in Human Plasma for Clinical Applications Using High-Performance Liquid Chromatography–Tandem Mass Spectrometry 2025 ·Therapeutic Drug Monitoring ·Jingjing Wu, (unknown), (unknown), Yawen Wang, Kejing Tang, Jing Xu, (unknown)	0
4	Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study 2025 ·Lung Cancer ·Lin Wu, Junling Li, Chong‐Rui Xu, Bivas Biswas, (unknown), Kejing Tang, Huijuan Wang, Ziling Liu, Ullas Batra, Gwo Fuang Ho, (unknown), You Lü, (unknown), Lye Mun Tho, Jun Zhao, (unknown), (unknown), (unknown), (unknown), Yi‐Long Wu	0
5	Genetic landscape and evolution of Acinetobacter pittii, an underestimated emerging nosocomial pathogen 2025 ·Communications Biology ·Shengke Wang, Yan Zhou, (unknown), Kejing Tang, Danqi Wang, (unknown), (unknown), Sheng Ye, Jie Yan, (unknown), Zhemin Zhou, Jimei Du	3
6	Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study 2025 ·Lupus Science & Medicine ·(unknown), (unknown), Lizhi Chen, Lu Zhang, Yifan Zheng, Kejing Tang, Xiaoyun Jiang, Pan Chen	0
7	IL-17A, IL-23R, FCGR3A are associated with neuropsychiatric systemic lupus erythematosus susceptibility in pediatric patients with lupus nephritis 2025 ·Cytokine ·(unknown), Lizhi Chen, Lu Zhang, Yifan Zheng, Xiaohong Liu, (unknown), Kejing Tang, Xiaoyun Jiang, Chen Pan	2
8	H3K27ac acts as a molecular switch for doxorubicin-induced activation of cardiotoxic genes 2024 ·Clinical Epigenetics ·(unknown), (unknown), Jia Li, (unknown), (unknown), Yubo Tang, Xiao Chen, Jie Chen, Kejing Tang, Chao Wei	3
9	PL04.10 Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial 2024 ·Journal of Thoracic Oncology ·(unknown), (unknown), William W. Feng, Janice J.N. Li, Hong‐Hong Yan, Bin Xu, J. Zhao, Ya Jia, Kejing Tang, Yingfeng Li, Chengzhi Zhou, Fan Yu, Chong‐Rui Xu, Yu Sun, Hua‐Jun Chen	2
10	The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis 2024 ·The Clinical Respiratory Journal ·(unknown), (unknown), Min Huang, Kejing Tang, Jing Xu, (unknown)	2
11	Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial 2024 ·Cancer Research ·Ying Cheng, Lin Wu, Yong Fang, Yun Fan, Xingya Li, Mingjun Zhang, Yan Yu, Yu Yao, Ruilian Xu, Jun Guo, Huaping Yang, Jian Fang, Feng Luo, Xuhong Min, Kejing Tang, Jie Hu, Yunru Chen, Rui Mao, (unknown), (unknown)	5
12	A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells 2024 ·Cellular Oncology ·Zhifeng Yan, Runxia Gu, Haotian Ma, (unknown), Ting Zhang, Yingxi Xu, Shaowei Qiu, Haiyan Xing, Kejing Tang, Tian Zheng, Qing Rao, Min Wang, Jianxiang Wang	6
13	Combination targeted therapy with avapritinib and sunitinib in patients with refractory gastrointestinal stromal tumors after failure of standard treatments: A small prospective pilot study. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), Xiaodan Guo, (unknown), Chunhui Wu, Aiting Jiang, Shirong Cai, Yulong He, Kejing Tang	1
14	Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells 2021 ·Blood Cancer Journal ·(unknown), Yingxi Xu, (unknown), Qing Rao, Haiyan Xing, Tian Zheng, Kejing Tang, Min Wang, (unknown)	27
15	Single-cell transcriptome of early hematopoiesis guides arterial endothelial-enhanced functional T cell generation from human PSCs 2021 ·Science Advances ·Jun Shen, Yingxi Xu, Shuo Zhang, (unknown), (unknown), (unknown), Kejing Tang, (unknown), Xinjie Li, (unknown), Min Wang, Jianxiang Wang, Xin Li, Zack Z. Wang, Tao Cheng	18
16	CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype 2018 ·Human Gene Therapy ·Saisai Li, (unknown), Yingxi Xu, Jia Liu, Na An, Ying Wang, Haiyan Xing, Tian Zheng, Kejing Tang, (unknown), Qing Rao, Min Wang, Jianxiang Wang	61
17	Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells 2018 ·Human Gene Therapy ·Yingxi Xu, Saisai Li, Ying Wang, Jia Liu, (unknown), Haiyan Xing, Tian Zheng, Kejing Tang, (unknown), Qing Rao, Dongsheng Xiong, Min Wang, Jianxiang Wang	22
18	Regulatory T Cells Promote the Stemness of Acute Myeloid Leukemia Cells through IL10 Cytokine Related Signaling Pathway 2017 ·Blood ·Yingxi Xu, (unknown), Jia Liu, Ying Wang, Saisai Li, Haiyan Xing, Kejing Tang, Tian Zheng, Qing Rao, Min Wang, Jianxiang Wang	3
19	Activation of Rac1 GTPase promotes leukemia cell chemotherapy resistance, quiescence and niche interaction 2013 ·Molecular Oncology ·Jiying Wang, (unknown), Pei Yu, Shuying Chen, Haiyan Xing, Yirui Chen, Min Wang, Kejing Tang, Tian Zheng, Qing Rao, Jianxiang Wang	35
20	Overexpression of Midkine promotes the viability of BA/F3 cells 2009 ·Biochemical and Biophysical Research Communications ·Yang Wang, Haiyan Xing, Tian Zheng, Kejing Tang, Jiying Wang, Zhifang Xu, Qing Rao, Min Wang, Jianxiang Wang	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact